Figure 1.

KDM4C inhibition enhances CD8⁺ T cell infiltration and migration. (A) C57BL/6 mice were injected subcutaneously with 1×10⁶ stable Lewis cells (sh-control or sh-KDM4C). The volumes of the subcutaneously transplanted tumors were measured every 3 days, and the growth curves were drawn (mean±SEM; n=10; ***p<0.001). (B) All subcutaneously transplanted tumor weights were measured (n=10/group, ***p<0.001). (C) Mice bearing Lewis tumors were treated with SD70 (10 mg/kg) when the tumor volume reached a calculated average of 100 mm³. After administration for five consecutive days, SD70 was administered once every 3 days (mean±SEM; n=8; ***p<0.001). (D) All subcutaneously transplanted tumor weights of each group (n=8/group, ***p<0.001). (E, F) The percentages of CD8⁺ T cells in CD3⁺ cells in tumor tissues after the indicated treatment. The mean±SD is shown. **P<0.01, ***p<0.001. (G, H) Left panel: representative immunohistochemical staining images of CD8⁺ T cells in CD3⁺ cells in tumor tissues after the indicated treatment. Scale bar: 100 µm. Right panel: CD8⁺ T cells counted with ImageJ software. Three fields were selected for each sample. ***p<0.001. (I, J) The percentages of proliferating CD8⁺ T cells were analyzed by Ki67 staining. The mean±SD is shown. (K, L) At 72 hours after CFSE staining, the proliferation of CD8⁺ T cells was measured by flow cytometry. ***P<0.001. (M) Schematic diagram of in vitro CD8⁺ T cell migration assays. (N, O) The number of CD8⁺ T cells passing through the membrane of a Transwell system was calculated by flow cytometry. The mean±SD is shown. ***P<0.001.